Exhibit 17



Teva Worldwide

Stock Contact Us Hebrew



About

Products

Research

Responsibility

Media

Investors

Home page > About > Actavis Integration

Actavis Integration

Company Profile

Corporate Officers

Corporate Governance

Our History

Teva Acquires Actavis Generics

Joining forces to build our new future









At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future.

The acquisition delivers on these objectives, while enabling us to take a leading position in our transforming industry.

This strategic acquisition brings together two leading generics businesses with complementary strengths, brands and cultures, providing patients with more affordable access to quality medicines, and creating significant financial benefits for Teva stockholders.

Our newly combined company offers the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale.

Read more in the press release

Actavis Regional Contacts

Teva welcomes our Actavis Generics local markets. We want to ensure that each region continues to receive the support it needs during this time of

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy and Cookie Notice.




11/3/2016 ase 1:19-md-02875-RMB-SAK Document 2869vil 8 tegrafiiled 11/05/19 Page 3 of 5 PageID:

General
inquiries
Medical Affairs
Actavis site
Teva site

General
inquiries
Medical Affairs
Actavis site
Teva site


General
inquiries
Medical Affairs
Actavis site
Teva site



This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our <u>Privacy and Cookie Notice</u>.



11/3/2016 ase 1:19-md-02875-RMB-SAK Document 2860 vil 8 htegrafii led 11/05/19 Page 4 of 5 PageID:



This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our <u>Privacy and Cookie Notice</u>.



11/3/2016 ase 1:19-md-02875-RMB-SAK Document 2860 vil 8 htegrafii led 11/05/19 Page 5 of 5 PageID:

3518 Tomer Amitai, 972 (3) 926-7656 (Israel)

About	Products	Research	Responsibility	Media	Investors	Careers
Company Profile Corporate Officers Corporate Governance Our History	Specialty Generic Products Generic FAQ Over the Counter (OTC) API Quality	Our Philosophy Patient Promise Pipeline Clinical Trials Biopharmaceuticals	Social Impact Positions & Policies Patient Advocacy	Latest News Featured Stories Social Media	Press Releases Events & Presentations Financial Information Debt Information Stock Information Corporate Governance Investor Resources	Dare to be different Our Guiding Values Leadership Development Working at Teva Meet the [Experts]
Follow Teva:						
Legal Notes Supplier FAQ's	Data Privacy	PhV Privacy Notic	e TAPI	Teva Supplier C	Code of Conduct © 2018 Teva Pharr	Sitemap maceutical Industries Ltd.

This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our **Privacy and Cookie Notice**.

